• Home
  • Robert J Morlock
Robert J Morlock

Robert J Morlock

PhD

About

181
Publications
14,436
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
1,470
Citations
Introduction
Health Services Researcher focused on population health, patient preferences, PRO development\validation, economics of treatment interventions and placebo response.
Additional affiliations
January 2016 - present
Acumen Health Research Institute
Position
  • Scientific Collaborator
January 2013 - present
Pro-Spectus
Position
  • Scientific Collaborator
January 2013 - present
Metabolic Markets, LLC
Position
  • Scientific Collaborator

Publications

Publications (181)
Article
Full-text available
Introduction: The patient experience with prostate cancer differs throughout the disease continuum, with health-related quality of life (HRQoL) and symptoms worsening as the disease progresses. To understand the prostate cancer experience, it is important to understand the experience of same-aged men without prostate cancer as a basis for compariso...
Article
Background By definition, uncontrolled gout (UG) cannot be managed with oral urate lowering therapies (ULTs) and is associated with substantial morbidity. UG, also known as refractory gout, results in escalated treatment and management. Recent American College of Rheumatology guidelines recommend treating gout to serum uric acid targets; if targets...
Article
Background The novel vaginal pH modulator (VPM; Phexxi) is a non-hormonal, woman-controlled, on-demand, water-based, surfactant-free contraceptive vaginal gel; VPM has also been cleared by the Food and Drug Administration for use as a personal lubricant. Aim The aim of this study is to report on sexual satisfaction results from the phase 3 AMPOWER...
Article
49 Background: Trifluridine/tipiracil (FTD/TPI) and regorafenib are among the limited treatment options in later lines of therapy for patients with advanced colorectal cancer (CRC). While these treatments have demonstrated similar efficacy, differences have been observed in tolerability and data on the impact of such differences on real-world outco...
Article
Full-text available
Introduction: Popular media coverage of psychedelics use, growing research into this class of compounds for psychiatry and decriminalization initiatives, are transforming the public perception of psychedelics. However, little is known about levels of knowledge and psychedelic mushroom (PM) use among American adults. Methods: We examined PM use and...
Article
Full-text available
The placebo response is a highly complex psychosocial-biological phenomenon that has challenged drug development for decades, particularly in neurological and psychiatric disease. While decades of research have aimed to understand clinical trial factors that contribute to the placebo response, a comprehensive solution to manage the placebo response...
Poster
Full-text available
Using a self-reported assessment (PRPS) to identify potential placebo response by established anxiety and depression severity thresholds. The PRPS can be used at a single screening or baseline visit to assess the impact of PBO response across treatment arms. Use of the PRPS improves signal to noise assessment when evaluating new therapies in condit...
Preprint
Full-text available
Introduction: Popular media coverage, including of recent positive late stage clinical trials in depression and PTSD, and decriminalization initiatives, are transforming the public perception of psychedelics. However, little is known about levels of knowledge and personal use of psychedelic mushroom(s) (PM) among American adults. Methods: We examin...
Article
Full-text available
Background Zolbetuximab plus first-line EOX (epirubicin, oxaliplatin, capecitabine; ZOL/EOX) significantly prolonged progression-free survival and overall survival in the FAST trial vs EOX alone. We report the patient-reported outcomes (PROs) of FAST in patients with advanced gastroesophageal adenocarcinoma. Methods Patients were randomized to ZOL...
Article
Full-text available
Background Early recognition of COVID-19 cases is essential for effective public health measures aimed at isolation of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS–COV-2). The objective of this study was to describe characteristics, self-reported symptoms, and predictors of testing positive for SARS-CoV-2 infectio...
Article
Full-text available
Background In the ARCHES study in metastatic hormone-sensitive prostate cancer (mHSPC), enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) versus ADT alone. Objective To evaluate patient-reported outcomes (PROs) to week 73. Design, setting, and participants ARCHES (NCT02677896) was a random...
Article
Objectifs L’enzalutamide (ENZA) apporte un bénéfice aux hommes atteints d’un cancer de la prostate résistant à la castration (CPRC). ARCHES, étude de phase III en double aveugle versus placebo (PBO), évalue l’efficacité d’ENZA associé à une suppression androgénique (TSA) dans le cancer de la prostate hormono-sensible métastatique (CPHSm). Les résul...
Article
Full-text available
Background ENZA, a potent androgen receptor inhibitor, provides benefit in men with castration-resistant prostate cancer (CRPC). In post hoc analyses, the role of ENZA + ADT in mHSPC patients (pts) randomized within the multinational, double-blind, PBO-controlled, Phase 3 ARCHES study (NCT02677896) was determined by disease volume and risk group st...
Article
Full-text available
Objective Evaluate the association between gout and risk of advanced chronic kidney disease (CKD).DesignRetrospective matched cohort study.SettingUK Clinical Practice Research Datalink.ParticipantsThe analysis included data for 68 897 patients with gout and 554 964 matched patients without gout. Patients were aged ≥18 years, registered at UK practi...
Article
5044 Background: The Phase 3 ARCHES trial (NCT02677896) evaluated the efficacy and safety of ENZ + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT in 1150 men with mHSPC. Here we report patient-reported outcome (PRO) data using Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Brief Pain Inventory Short Form (BPI-SF). Methods:...
Article
Full-text available
Background Uncontrolled gout can cause significant joint and organ damage and has been associated with impairments in quality of life and high economic cost. Gout has also been associated with other comorbid diseases, such as chronic kidney disease. The current study explored if healthcare resource utilization (HRU) and survival differs between pat...
Article
233 Background: PROSPER data were analyzed to assess the relationship between time to worsening of urinary, bowel, and hormonal treatment-related symptoms and prostate-specific antigen (PSA) response, and the longitudinal association between symptom changes and metastasis-free survival (MFS). Methods: 1401 patients (pts) with nmCRPC at high metasta...
Article
Background: In the PROSPER trial, enzalutamide significantly improved metastasis-free survival in patients with non-metastatic, castration-resistant prostate cancer. Here, we report the results of patient-reported outcomes of this study. Methods: In the randomised, double-blind, placebo-controlled, phase 3 PROSPER trial, done at 254 study sites...
Article
Background There is little information available on health-related quality of life in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. This study aimed to develop a conceptual model that describes patients’ experiences of living with this condition. Methods This was a cross-sectional, non-interventional qualitative...
Article
Full-text available
Gastric cancer (GC) and gastroesophageal junction cancers (GEJCs) are the third leading cause of cancer-related death worldwide. Although several studies have evaluated the epidemiology and management of GC and GEJC, to our knowledge, no global estimates of the economic burden of GC and GEJC have yet been reported. This targeted literature review w...
Article
Full-text available
Objectifs Les données de l’essai prosper ont été analysées pour déterminer (a) le lien entre le délai de détérioration de la qdv et la réponse de l’antigène prostatique spécifique (psa) et (b) l’association entre la qdv et la survie sans métastase (mfs). Méthodes Dans l’essai prosper, 1401 patients présentant un cprcnm à haut risque de métastases...
Article
Aim: To evaluate the burden of uncontrolled gout by examining estimated costs and cost drivers. Materials and Methods: Data from the 2012 and 2013 US National Health and Wellness Survey (NHWS; 2012 NHWS N = 71,157 and 2013 NHWS N = 75,000) were utilized in this study. Based on self-reported gout diagnosis and gout symptoms, respondents were categor...
Article
Background: As type 2 diabetes (T2D) progresses, administering basal and bolus insulin through multiple daily injections (MDI) is often required to achieve target control, although many people fail to achieve target levels. Continuous subcutaneous insulin infusion (CSII) treatment with traditional pumps has proven effective in this population, but...
Article
Full-text available
Available descriptive statistics for patients with metastatic basal cell carcinoma (mBCC) are limited. To describe disease characteristics, treatment patterns, survival outcomes, and prognostic factors of patients with mBCC, we conducted a retrospective review of electronic health records in the Department of Veterans Affairs (VA). The primary outc...
Article
Full-text available
Purpose: Measurement development in hard-to-reach populations can pose methodological challenges. Item response theory (IRT) is a useful statistical tool, but often requires large samples. We describe the use of longitudinal IRT models as a pragmatic approach to instrument development when large samples are not feasible. Methods: The statistical...
Conference Paper
Background Gout and type 2 diabetes mellitus (T2DM) are common in the United States (US), but little is known about potential associations of T2DM and hyperuricemia/gout with clinical outcomes. This study examined variations in gout severity, management, and health care utilisation among gout patients with and without T2DM. Methods Data were asses...
Article
54 Background: In the FAST study, IMAB362 (loading dose 800 mg/m ² then 600 mg/m ² d1 qd21) plus EOX (epirubicin 50 mg/m ² and oxaliplatin 130 mg/m ² d1, and capecitabine 625 mg/m ² bid) was compared with EOX alone in patients with advanced/metastatic gastric (GA), gastroesophageal (GE), and gastroesophageal junction (GEJ) adenocarcinoma. The FAST...
Article
Full-text available
Introduction:. Genotyping-based treatment decisions may optimize treatment response and minimize adverse drug events (ADEs) in patients with chronic pain. Objectives:. To estimate the financial impact of genotyping-based treatment decisions in patients with moderate to severe chronic pain in a managed care setting. Methods:. A budget impact model w...
Article
Full-text available
Background: Gout, hyperuricemia, and cardiovascular disease (CVD) are prevalent conditions in the United States, and while they share common risk factors such as obesity, hypertension, hypercholesterolemia, and type 2 diabetes mellitus, relatively little is known about what patient and disease characteristics may link CVD with hyperuricemia and go...
Conference Paper
Background Hyperuricemia is associated with worsened outcomes in patients with heart failure (HF). However, little is known about the association between gout and HF. Objectives To assess the impact of gout control on the rate of hospitalization for acute HF in a prevalent gout population. Methods This retrospective database analysis used data fr...
Conference Paper
Background Gout and osteoarthritis (OA) are common in the United States, but little is known about potential associations of OA and hyperuricemia/gout with clinical outcomes. Objectives This study examined variations in gout severity, management, and healthcare utilization among gout patients with and without OA. Methods Data were assessed from a...
Conference Paper
Background Although allopurinol is FDA approved for up to 800 mg per day and EMEA authorized for up to 900 mg per day, most patients receive 300 mg per day or less. Objectives To describe physician, patient, and treatment characteristics in gout patients treated with allopurinol and to assess the proportion of patients reaching serum uric acid (sU...
Conference Paper
Background Gout is a common form of inflammatory arthritis. Treatment guidelines recommend a target serum urate (sUA) ≤6mg/dL. ACR and EULAR treatment guidelines indicate sUA targets may need to be surpassed to achieve treatment benefits in a subset of patient that continue to flare and/or have tophi. Methods Data were assessed from a survey of ph...
Article
Full-text available
AIM To determine the impact of allopurinol non-adherence as a proxy for uncontrolled disease on primary prevention of end-stage renal disease (ESRD). METHODS A cohort of 2752 patients with gout diagnosis was reconstructed using the Québec Régie de l’assurance maladie du Québec and MedEcho administrative databases. Eligible patients were new users...
Article
Full-text available
Objective Many publications describe preferences for colorectal cancer (CRC) screening; however, few studies elicited preferences for anticancer-drug treatment for metastatic CRC (mCRC). This study was designed to elicit preferences and risk tolerance among patients and oncologists in the USA for anticancer drugs to treat mCRC. Materials and metho...
Article
Purpose: To develop a questionnaire quantifying spectacle independence following cataract surgery. Design: Questionnaire design and validation study. Methods: A literature review, expert clinical interviews, and patient interviews were undertaken to develop a patient-reported questionnaire assessing spectacle independence. Draft items were ass...
Article
Background: Gout is a chronic inflammatory disorder associated with elevated levels of serum uric acid (sUA), resulting in urate crystal deposits in soft tissues. Uncontrolled gout can lead to bone erosion and joint destruction, kidney stones, and uric acid nephropathy. Gout is treatable with medication and lifestyle change. Long-term sUA monitorin...
Article
Background Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) investigated for the treatment of gout in combination with xanthine oxidase inhibitors. In two Phase 3 clinical trials examining lesinurad in combination with allopurinol, patients with non-tophaceous gout demonstrated a reduction in gout flares over the 12-month...
Article
Background Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) investigated for treatment of gout in combination with xanthine oxidase inhibitors (XOI). Objectives Investigate efficacy as assessed by a composite endpoint of serum uric acid (sUA) target and no flares in gout patients with inadequate response to XOIs alone fro...
Article
Background Gout is a common inflammatory arthritis and its worldwide prevalence is increasing. EULAR and American College of Rheumatology guidelines recommend a target sUA <6 mg/dL, with a target of <5 mg/dL in those with more severe symptomatic disease. Patients with significant crystal burden are assumed to have higher humanistic and economic bur...
Article
Background Even though well-designed literature-based meta-analyses have confirmed the link between hyperuricemia and the risk for cardiovascular disease (CVD), it is known that study-level analyses can lead to biased assessments, and use of aggregated summary values has some limitations for explaining the heterogeneity. An individual patient data...
Article
Background Gout is the most common cause of inflammatory arthritis in men and older women, and there are very few studies on the rate of joint replacement among patients with diagnosed gout compared to those without gout. Objectives To assess the risk of joint replacement among patients with diagnosed gout compared to patients without gout diagnos...
Article
Full-text available
IntroductionPatients with gout have numerous comorbidities. We aimed to estimate the prevalence and incidence rates of renal and cardiovascular morbidities in trial-aligned patients with established gout in Germany (DE), the United Kingdom (UK), the United States (US), and France (FR). Methods This longitudinal cohort study used retrospective data...